CorMatrix Cardiovascular Secures FDA 510(k) Clearance for Cor Patch Epicardial Repair Patch to Treat Myocardial Infarction-Related Atrial Damage

VCBeat (WeChat ID: vcbeat) has learned from foreign media that medical device company CorMatrix Cardiovascular recently announced that its Cor Patch epicardial patch has received FDA 510(k) clearance for repairing atrial damage caused by myocardial infarction, including damage to the left ventricular wall, right ventricular wall, and valves.

Headquartered in Roswell, Georgia, USA, CorMatrix Cardiovascular is a medical device company specializing in the development of biomaterial-based devices. It was co-founded in December 2001 by Dr. Robert G. Matheny, a cardiovascular surgeon, and David Camp, an entrepreneur in the field of cardiovascular medical devices. The company primarily leverages its proprietary technology to develop devices capable of repairing human cardiac tissue. This proprietary technology is based on extracellular matrix (ECM) technology, designed to address clinical challenges associated with congestive heart failure, heart valves, and cardiovascular diseases.

Currently, six of the company’s relevant devices have been used in over 220,000 cardiovascular regenerative procedures. CorMatrix Cardiovascular is developing second-generation ECM technology, and the recently approved Cor Patch epicardial repair patch marks the company’s formal entry into the next-generation ECM cardiac surgery market.

“Using the Cor Patch technology allows for the repair of myocardial tissue following injury. For patients undergoing cardiac surgery, this could be a life-changing advancement that enhances blood supply to damaged areas of the heart,” said Dr. Paul Fedak, Professor of Cardiac Surgery at the Cumming School of Medicine, University of Calgary, in a press release. “My translational research provides a critical data foundation to support the application of this epicardial patch during coronary artery bypass grafting. This technology enables surgeons to bypass obstructed vessels and directly target compromised myocardium.”

CorMatrix Cardiovascular states on its official website that the patch minimizes post-implantation inflammatory responses and provides the structural support required for epicardial tissue. The Cor Patch is available in five package configurations and comes in two sizes: 5 cm x 5 cm and 7 cm x 10 cm.

Robert Matheny, Chief Medical and Scientific Officer (CM&SO) of CorMatrix Cardiovascular, stated, “We have gained a deeper understanding of the potential physiological mechanisms of regenerative medicine and ECM technology. The Cor Patch marks our entry into the market for epicardial tissue repair, and our R&D pipeline will soon introduce several highly compelling products.”

“Cor Patch is the next-generation ECM product approved by the FDA for epicardial tissue repair,” added Edgar Rey, CEO of CorMatrix Cardiovascular. “The launch of the Cor Patch epicardial patch in the cardiac surgery market underscores our rapidly expanding pipeline of next-generation ECM products and patient solutions.”

(Compiled by Wang Chan)